Mid-Size Pharmaceuticals Market Report 2026

Mid-Size Pharmaceuticals Market Overview

• Mid-Size Pharmaceuticals market size has reached to $760.71 billion in 2025 • Expected to grow to $1059.05 billion in 2030 at a compound annual growth rate (CAGR) of 7% • Growth Driver: Rising Prevalence Of Chronic Diseases Fuels Growth In Mid-Size Pharmaceuticals Market • Market Trend: Mid-Size Pharmaceuticals Embrace Precision Medicine With Innovative Platforms • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Mid-Size Pharmaceuticals Market?

Mid-sized pharmaceuticals are companies with annual revenue ranging from $1 billion to $10 billion. Mid-sized pharmaceutical companies include drug development, niche market targeting, regional presence, partnerships, generic drug manufacturing, and contract manufacturing. The main types of drug development of mid-size pharmaceuticals are in-house and outsourced. In-house refers to activities or functions performed within an organization or company by its employees or departments rather than outsourcing them to external parties or contractors. In-house in mid-size pharmaceuticals refers to the activities or functions that are conducted internally within the pharmaceutical company by its employees or departments, rather than being outsourced to external entities. This can include various functions such as research and development, manufacturing, quality control, regulatory affairs, sales and marketing, and other operational aspects of the pharmaceutical business. It has prescription and over-the-counter facilities that sell medicines in the form of tablets, capsules, injectables, sprays, and others that are suitable for treating cardiovascular diseases, pain management, diabetes, cancer, and others.

What Is The Mid-Size Pharmaceuticals Market Growth Forecast?

The mid-size pharmaceuticals market size is expected to see strong growth in the next few years. It will grow to $1059.05 billion in 2030 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to advancements in personalized medicine, increased outsourcing of cros & cmos, adoption of ai-driven drug discovery, expansion of digital health platforms, growth in specialty pharmaceuticals. Major trends in the forecast period include niche drug development focus, regional market expansion, strategic partnerships & collaborations, generic drug manufacturing growth, contract manufacturing optimization.

Global Mid-Size Pharmaceuticals Market Segmentation

1) By Drug Development Type: In-House, Outsource 2) By Type: Prescription, Over The Counter 3) By Formulation: Tablets, Capsules, Injectables, Sprays, Other Formulations 4) By Application: Cardiovascular Diseases, Pain Management, Diabetes, Cancer, Other Conditions Subsegments: 1) By In-House: Research And Development (R&D) Departments, Clinical Trials Management 2) By Outsource: Contract Research Organizations (CROs), Contract Manufacturing Organizations (CMOs)

What Is The Driver Of The Mid-Size Pharmaceuticals Market?

The increased prevalence of chronic diseases is expected to propel the growth of mid-size pharmaceuticals market going forward. Chronic diseases, also known as non-communicable diseases, are long-term medical conditions that require ongoing management and treatment which leads to high demand for medications. Mass spectrometry techniques are used for the identification, quantification, and analysis of biomarkers and metabolites associated with chronic diseases. A rise in the prevalence of chronic diseases will contribute to the growth of the mid-size pharmaceuticals market. For instance, in June 2024, according to the National Health Service, a UK-based government department, 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition with elevated blood sugar levels, not high enough to be classified as diabetes) in 2023, marking an 18% increase from 3,065,825 cases in 2022. Therefore, the increasing prevalence of chronic diseases is driving the growth of the mid-size pharmaceuticals industry.

Key Players In The Global Mid-Size Pharmaceuticals Market

Major companies operating in the mid-size pharmaceuticals market are Baxter International Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Alexion Pharmaceuticals Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Eisai Co. Ltd., Les Laboratoires Servier S.A., Perrigo Co Plc, Aurobindo Pharma Limited., Cipla Limited, Hikma Pharmaceuticals, Endo International plc, Taisho Pharmaceutical Holdings Co. Ltd., BioMarin Pharmaceutical Inc., Mallinckrodt Plc, Exelixis Inc., Mylan Pharmaceuticals Inc., Neurocrine Biosciences Inc., Kyowa Kirin Co. Ltd., Emergent BioSolutions Inc.

Global Mid-Size Pharmaceuticals Market Trends and Insights

Major companies operating in mid-size pharmaceuticals are focusing on product development and launches such as precision medicine platforms to sustain their position in the market. A precision medicine platform refers to an advanced technology or system designed to tailor medical treatment and interventions to the specific characteristics of individual patients. For instance, in February 2023, C4X Discovery Holdings PLC, a UK-based mid-size pharmaceutical company, unveiled its innovative precision medicine platform, PatientSeek. This platform is designed to identify patients who are most likely to benefit from a specific medication based on their genetic makeup. The launch of PatientSeek follows successful validation in patient stratification, where a subgroup of patients responding positively to treatment was identified during a retrospective analysis of a Phase 3 clinical trial for Parkinson's disease. This development marks a significant step in leveraging genetics for targeted and effective medication strategies, showcasing the potential of precision medicine in optimizing treatment outcomes.

What Are Latest Mergers And Acquisitions In The Mid-Size Pharmaceuticals Market?

In March 2023, Sun Pharmaceutical Industries Limited, an India-based pharmaceutical company, acquired Concert Pharmaceuticals for $576 Million. Through this acquisition, Sun Pharmaceutical Industries Limited gains all outstanding shares of Concert’s common stock and the addition of deuruxolitinib, a novel, deuterated, oral JAK1/2 inhibitor, for the potential treatment of adult patients with moderate to severe alopecia areata to its pipeline. Concert Pharmaceuticals Inc. is a US-based late-stage clinical mid-sized biopharmaceutical company developing innovative medicines with unique therapeutic properties.

Regional Insights

North America was the largest region in the mid-size pharmaceutical market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Mid-Size Pharmaceuticals Market?

The mid-sized pharmaceuticals market consists of revenues earned by entities providing pharmaceutical services such as drug development, research activities, generic drug manufacturing, and contract manufacturing. The market value includes the value of related goods sold by the service provider or included within the service offering. The mid-sized pharmaceuticals market consists of the sales of goods such as prescription drugs, over-the-counter medications, generic drugs, and other pharmaceutical products targeting specific therapeutic areas or niche markets. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Mid-Size Pharmaceuticals Market Report 2026?

The mid-size pharmaceuticals market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the mid-size pharmaceuticals industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.